The New Payer Dogma: US FDA Approved Drugs Have 'Less Evidence'
Executive Summary
It is now a common assertion among insurers that one of the many challenges they face in covering high-priced specialty therapies is that drugs are approved with “less evidence” than used to be the case. That is more myth than reality – but a very dangerous myth if it isn’t corrected by the US FDA and the drug industry.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
